BRPI0717035A2 - Moduladores de benzotriazol cinase - Google Patents

Moduladores de benzotriazol cinase

Info

Publication number: BRPI0717035A2
Authority: BR; Brazil
Prior art keywords: benzotriazol; kinase modulators; modulators; kinase; benzotriazol kinase
Prior art date: 2006-09-08

Application number

BRPI0717035-1A2A

Other languages

English (en)

Inventor

David Michael Goldstein

Leyi Gong

Christophe Michoud

Wylie Solang Palmer

Achyutharao Sidduri

Original Assignee

Hoffmann La Roche

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2006-09-08

Filing date

2007-08-30

Publication date

2014-11-25

2007-08-30 Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche

2014-11-25 Publication of BRPI0717035A2 publication Critical patent/BRPI0717035A2/pt

2021-05-04 Publication of BRPI0717035B1 publication Critical patent/BRPI0717035B1/pt

2021-05-25 Publication of BRPI0717035B8 publication Critical patent/BRPI0717035B8/pt

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4192—1,2,3-Triazoles
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Public Health (AREA)
Life Sciences & Earth Sciences (AREA)
Veterinary Medicine (AREA)
General Health & Medical Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Medicinal Chemistry (AREA)
Animal Behavior & Ethology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Biomedical Technology (AREA)
Neurology (AREA)
Neurosurgery (AREA)
Immunology (AREA)
Diabetes (AREA)
Pulmonology (AREA)
Obesity (AREA)
Hematology (AREA)
Rheumatology (AREA)
Emergency Medicine (AREA)
Cardiology (AREA)
Endocrinology (AREA)
Psychology (AREA)
Pain & Pain Management (AREA)
Heart & Thoracic Surgery (AREA)
Hospice & Palliative Care (AREA)
Psychiatry (AREA)
Orthopedic Medicine & Surgery (AREA)
Physical Education & Sports Medicine (AREA)
Epidemiology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Plural Heterocyclic Compounds (AREA)

BRPI0717035A 2006-09-08 2007-08-30 moduladores de benzotriazol cinase BRPI0717035B8 (pt)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US84309006P	2006-09-08	2006-09-08
US60/843,090		2006-09-08
PCT/EP2007/059040 WO2008028860A1 (en)	2006-09-08	2007-08-30	Benzotriazole kinase modulators

Publications (3)

Publication Number	Publication Date
BRPI0717035A2 true BRPI0717035A2 (pt)	2014-11-25
BRPI0717035B1 BRPI0717035B1 (pt)	2021-05-04
BRPI0717035B8 BRPI0717035B8 (pt)	2021-05-25

Family

ID=38893293

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
BRPI0717035A BRPI0717035B8 (pt)	2006-09-08	2007-08-30	moduladores de benzotriazol cinase

Country Status (17)

Country	Link
US (1)	US8962622B2 (pt)
EP (1)	EP2066319B1 (pt)
JP (1)	JP5325783B2 (pt)
KR (1)	KR101177729B1 (pt)
CN (1)	CN101511359B (pt)
AR (1)	AR062666A1 (pt)
AT (1)	ATE543498T1 (pt)
AU (1)	AU2007293917B2 (pt)
BR (1)	BRPI0717035B8 (pt)
CA (1)	CA2662998C (pt)
CL (1)	CL2007002572A1 (pt)
ES (1)	ES2378577T3 (pt)
IL (1)	IL197015A (pt)
MX (1)	MX2009002229A (pt)
PE (1)	PE20080659A1 (pt)
TW (1)	TW200819440A (pt)
WO (1)	WO2008028860A1 (pt)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US20040082509A1 (en)	1999-10-12	2004-04-29	Christophe Bonny	Cell-permeable peptide inhibitors of the JNK signal transduction pathway
US8183339B1 (en)	1999-10-12	2012-05-22	Xigen S.A.	Cell-permeable peptide inhibitors of the JNK signal transduction pathway
WO2007031098A1 (en)	2005-09-12	2007-03-22	Xigen S.A.	Cell-permeable peptide inhibitors of the jnk signal transduction pathway
US8080517B2 (en)	2005-09-12	2011-12-20	Xigen Sa	Cell-permeable peptide inhibitors of the JNK signal transduction pathway
EP2102194A1 (en)	2006-12-08	2009-09-23	F. Hoffmann-Roche AG	Substituted pyrimidines and their use as jnk modulators
CA2701275C (en) *	2007-10-23	2016-06-21	F. Hoffmann-La Roche Ag	Kinase inhibitors
WO2009138340A1 (en) *	2008-05-16	2009-11-19	F. Hoffmann-La Roche Ag	Inhibitors of jnk
WO2009143865A1 (en) *	2008-05-30	2009-12-03	Xigen S.A.	Use of cell-permeable peptide inhibitors of the jnk signal transduction pathway for the treatment of various diseases
WO2009143864A1 (en)	2008-05-30	2009-12-03	Xigen S.A.	Use of cell-permeable peptide inhibitors of the jnk signal transduction pathway for the treatment of chronic or non-chronic inflammatory digestive diseases
WO2010072228A1 (en)	2008-12-22	2010-07-01	Xigen S.A.	Novel transporter constructs and transporter cargo conjugate molecules
EP2401274B1 (en)	2009-02-24	2014-10-22	F. Hoffmann-La Roche AG	Imidazo[1,2-a]pyridines as jnk modulators
JP5784604B2 (ja) *	2009-08-10	2015-09-24	エフ．ホフマン−ラロシュアーゲーＦ．Ｈｏｆｆｍａｎｎ−ＬａＲｏｃｈｅＡｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ	Ｊｎｋ阻害剤
JP5916719B2 (ja) *	2010-06-04	2016-05-11	エフ．ホフマン−ラロシュアーゲーＦ．Ｈｏｆｆｍａｎｎ−ＬａＲｏｃｈｅＡｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ	Ｊｎｋの阻害剤として有用な２−アミノ−ピリミジン誘導体
EP2576559B1 (en) *	2010-06-04	2015-03-04	F.Hoffmann-La Roche Ag	Inhibitors of jnk
WO2011160653A1 (en)	2010-06-21	2011-12-29	Xigen S.A.	Novel jnk inhibitor molecules
CA2807036C (en)	2010-10-14	2018-01-16	Xigen S.A.	Use of cell-permeable peptide inhibitors of the jnk signal transduction pathway for the treatment of chronic or non-chronic inflammatory eye diseases
SG191974A1 (en) *	2011-02-09	2013-08-30	Lubrizol Corp	Asphaltene dispersant containing lubricating compositions
EP2567959B1 (en)	2011-09-12	2014-04-16	Sanofi	6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
WO2013091670A1 (en)	2011-12-21	2013-06-27	Xigen S.A.	Novel jnk inhibitor molecules for treatment of various diseases
ES2694829T3 (es)	2013-02-25	2018-12-27	Aurigene Discovery Technologies Limited	Derivados de benzotriazol trisustituido como inhibidores de dihidroorotato oxigenasa
EP3013353B1 (en)	2013-06-26	2021-04-21	Xigen Inflammation Ltd.	Cell-permeable peptide inhibitors of the jnk signal transduction pathway for the treatment of cystitis
WO2014206427A1 (en)	2013-06-26	2014-12-31	Xigen Inflammation Ltd.	New use of cell-permeable peptide inhibitors of the jnk signal transduction pathway for the treatment of various diseases
WO2015197097A1 (en)	2014-06-26	2015-12-30	Xigen Inflammation Ltd.	New use for jnk inhibitor molecules for treatment of various diseases
HRP20190039T1 (hr)	2014-04-04	2019-03-08	Syros Pharmaceuticals, Inc.	Inhibitori ciklin-ovisne kinaze 7 (cdk7)
WO2015193281A1 (en) *	2014-06-16	2015-12-23	Allinky Biopharma	P38 and jnk mapk inhibitors for the treatment and prophylaxis of degenerative diseases of the nervous system
WO2017204626A1 (en)	2016-05-24	2017-11-30	Stichting Het Nederlands Kanker Instituut-Antoni van Leeuwenhoek Ziekenhuis	Combination therapy - combined map2k4/map3k1 and mek/erk inhibition
WO2018029336A1 (en)	2016-08-12	2018-02-15	INSERM (Institut National de la Santé et de la Recherche Médicale)	Methods for determining whether a subject was administered with an activator of the ppar beta/delta pathway.
CN108117523B (zh) *	2016-11-29	2021-05-07	上海医药工业研究院	卤代尿嘧啶类化合物的制备方法
US20180369206A1 (en)	2017-04-24	2018-12-27	Aurigene Discovery Technologies Limited	Methods of Use for Trisubstituted Benzotriazole Derivatives as Dihydroorotate Oxygenase Inhibitors
CA3060390A1 (en)	2017-04-24	2018-11-01	Aurigene Discovery Technologies Limited	Methods of use for trisubstituted benzotriazole derivatives as dihydroorotate oxygenase inhibitors
AU2019223906B2 (en)	2018-02-20	2024-11-21	Les Laboratoires Servier	Methods of use for trisubstituted benzotriazole derivatives
EP4215244A4 (en) *	2020-09-15	2025-02-26	Mitsubishi Tanabe Pharma Corporation	Triazine compound salt, crystal form thereof, and production method therefor
CN114456126A (zh) *	2022-02-26	2022-05-10	郑州萃智医药科技有限公司	一种化合物的合成方法
CN115677595B (zh) *	2022-10-26	2024-06-14	江苏睿实生物科技有限公司	一种2,4,5-三氯嘧啶的制备方法

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6329380B1 (en)	1999-06-30	2001-12-11	Merck & Co., Inc.	SRC kinase inhibitor compounds
CA2383546A1 (en)	1999-06-30	2001-01-04	William H. Parsons	Src kinase inhibitor compounds
US20030004174A9 (en)	2000-02-17	2003-01-02	Armistead David M.	Kinase inhibitors
EP1554269A1 (en)	2002-07-09	2005-07-20	Vertex Pharmaceuticals Incorporated	Imidazoles, oxazoles and thiazoles with protein kinase inhibiting activities
GB0308466D0 (en)	2003-04-11	2003-05-21	Novartis Ag	Organic compounds
EP1758892B1 (en)	2004-06-10	2012-10-17	Irm Llc	Compounds and compositions as protein kinase inhibitors
WO2006038001A1 (en)	2004-10-06	2006-04-13	Celltech R & D Limited	Aminopyrimidine derivatives as jnk inhibitors
GB0500492D0 (en) *	2005-01-11	2005-02-16	Cyclacel Ltd	Compound
US20060281764A1 (en)	2005-06-10	2006-12-14	Gaul Michael D	Aminopyrimidines as kinase modulators
ES2336625T3 (es)	2006-03-22	2010-04-14	Vertex Pharmaceuticals Incorporated	Inhibidores de la proteina quinasa c-met para el tratamiento de trastornos proliferativos.

2007
- 2007-08-30 CN CN2007800334496A patent/CN101511359B/zh active Active
- 2007-08-30 WO PCT/EP2007/059040 patent/WO2008028860A1/en not_active Ceased
- 2007-08-30 AT AT07803049T patent/ATE543498T1/de active
- 2007-08-30 EP EP07803049A patent/EP2066319B1/en active Active
- 2007-08-30 MX MX2009002229A patent/MX2009002229A/es active IP Right Grant
- 2007-08-30 KR KR1020097004741A patent/KR101177729B1/ko active Active
- 2007-08-30 JP JP2009527118A patent/JP5325783B2/ja active Active
- 2007-08-30 AU AU2007293917A patent/AU2007293917B2/en active Active
- 2007-08-30 CA CA2662998A patent/CA2662998C/en active Active
- 2007-08-30 ES ES07803049T patent/ES2378577T3/es active Active
- 2007-08-30 BR BRPI0717035A patent/BRPI0717035B8/pt active IP Right Grant
- 2007-09-05 TW TW096133095A patent/TW200819440A/zh unknown
- 2007-09-05 CL CL200702572A patent/CL2007002572A1/es unknown
- 2007-09-06 AR ARP070103923A patent/AR062666A1/es active IP Right Grant
- 2007-09-06 PE PE2007001197A patent/PE20080659A1/es active IP Right Grant
- 2007-09-07 US US11/899,758 patent/US8962622B2/en active Active
2009
- 2009-02-12 IL IL197015A patent/IL197015A/en active IP Right Grant

Also Published As

Publication number	Publication date
ES2378577T3 (es)	2012-04-16
BRPI0717035B1 (pt)	2021-05-04
EP2066319B1 (en)	2012-02-01
US8962622B2 (en)	2015-02-24
BRPI0717035B8 (pt)	2021-05-25
JP2010502668A (ja)	2010-01-28
IL197015A (en)	2013-12-31
KR101177729B1 (ko)	2012-09-07
WO2008028860A1 (en)	2008-03-13
TW200819440A (en)	2008-05-01
AU2007293917A1 (en)	2008-03-13
CN101511359A (zh)	2009-08-19
CA2662998A1 (en)	2008-03-13
IL197015A0 (en)	2009-11-18
AU2007293917B2 (en)	2013-01-31
EP2066319A1 (en)	2009-06-10
US20080103142A1 (en)	2008-05-01
AR062666A1 (es)	2008-11-26
CL2007002572A1 (es)	2008-04-18
PE20080659A1 (es)	2008-05-17
ATE543498T1 (de)	2012-02-15
CA2662998C (en)	2015-10-06
CN101511359B (zh)	2012-09-05
JP5325783B2 (ja)	2013-10-23
MX2009002229A (es)	2009-03-16
KR20090040908A (ko)	2009-04-27

Publication	Publication Date	Title
BRPI0717035A2 (pt)	2014-11-25	Moduladores de benzotriazol cinase
BRPI0716549A2 (pt)	2013-09-24	moduladores de quinase associada de interleucina-1
EP2089308A4 (en)	2014-08-06	DONOR
CR10841A (es)	2009-06-30	Imidazotriazinas imidazopirimidinas inhibidores de cinasa
BRPI0813653A2 (pt)	2014-12-30	Compostos de imidazotiazol moduladores de sirtuína
BRPI0813651A2 (pt)	2014-12-30	Compostos de tiazolopiridina moduladores de sirtuína
BRPI0715704A2 (pt)	2013-09-17	dispensador de lenÇos quadrilongo
EP2040116A4 (en)	2010-07-14	LENS ARRAY
EP2214542A4 (en)	2014-03-12	ELECTROMANUAL DISPENSER
AT504580A3 (de)	2008-07-15	Scan-einrichtung
BRPI0716781A2 (pt)	2014-11-18	Inibidores da quinase
DE502007001629D1 (de)	2009-11-12	Rfahren
BRPI0813230A2 (pt)	2014-12-23	Moduladores de calicreína 7
ATE546437T1 (de)	2012-03-15	Aminomethyl-4-imidazole
BRPI0821773A2 (pt)	2015-06-16	Monossebacato derivado de pirazol
DE502007000218D1 (de)	2008-12-18	nsetzungen
DE602007000495D1 (de)	2009-03-12	Flüssigkeit-Koinfusionsgerät
DE112007003147A5 (de)	2009-09-24	Rohr-Biegevorrichtung
EP2016087A4 (en)	2012-08-15	HYDROGENATION PROCESS
DE502007001652D1 (de)	2009-11-12	Notöltank
DE502007005975D1 (de)	2011-01-27	Wischblatt
BRPI0719956A2 (pt)	2014-04-29	Radiofluoração
FI20060178A0 (fi)	2006-02-23	Pinnoitusmenetelmä
DE102006045567A8 (de)	2008-09-11	Crimpstabilisierung
DE112007001125A5 (de)	2009-02-05	Käfigmutter

Legal Events

Date	Code	Title	Description
2018-04-24	B06F	Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
2018-05-02	B07D	Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
2020-04-28	B07E	Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
2020-05-05	B06U	Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
2020-11-17	B06A	Patent application procedure suspended [chapter 6.1 patent gazette]
2021-02-23	B09A	Decision: intention to grant [chapter 9.1 patent gazette]
2021-05-04	B16A	Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]	Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 30/08/2007, OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME MEDIDA CAUTELAR DE 07/04/2021 - ADI 5.529/DF
2021-05-25	B16C	Correction of notification of the grant [chapter 16.3 patent gazette]	Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 30/08/2007 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF